CD90作为卵巢癌干细胞标志物的相关研究  

Study of CD90 as a Marker for Sorting Human Ovarian Cancer Stem Cells

作　　者：翁艳洁 周晓水 王常玉[1] 项涛 Weng Yanjie;Zhou Xiaoshui;Wang Changyu(Department of Obstetrics and Gynecology,Tongji Hospital Affiliated to Tongji Medical College,Huazhong University of Science and Technology,Hubei 430030,China)

机构地区：[1]华中科技大学同济医学院附属同济医院妇产科,武汉430030

出　　处：《医学研究杂志》2020年第12期45-49,共5页Journal of Medical Research

基　　金：湖北省自然科学基金资助项目(2019CFB154);中央高校基本科研业务费专项资金资助项目(2017KFYXJJ122)。

摘　　要：目的研究CD90作为分选卵巢癌干细胞标志物的可行性。方法选择笔者实验室制备的人卵巢癌顺铂耐药细胞株SKOV3-MD3,采用CD90单抗染色,应用流式细胞仪分选获得CD90^+细胞及CD90^-细胞。体外实验检测两个不同亚群细胞的体外悬浮球形成能力(自我更新能力)、分化潜能、表达干细胞标志物的差异,体内动物实验检测不同亚群细胞皮下成瘤能力是否有差异。结果人卵巢癌细胞SKOV3-MD3中存在具有干性特征的CD90^+细胞,CD90^+细胞比CD90^-细胞具有更高的体外悬浮球形成能力(自我更新能力)及分化潜能,表达更高水平的干细胞标志物,以及具有更强的皮下成瘤能力,差异有统计学意义。结论CD90可能是分选卵巢癌干细胞的分子学标志物。Objective To explore the possibility of CD90 as a marker in sorting human ovarian cancer stem cells.Methods Human ovarian cancer SKOV3-MD3 cells,resistant to cisplatin,were stained with CD90,and sorted to different subtypes by flow cytometer:CD90^+cells and CD90^-cells.The suspension sphere-forming capability(self-renewal capability),differentiation potential,the expression of stem cell markers and subcutaneous tumorigenicity in NOD/SCID mice in vivo were explored to analyze the different stemness of CD90^+and CD90^-cells.Results Human ovarian cancer CD90^+SKOV3-MD3 cells showed stemness.CD90^+cells showed higher sphere-forming capability(self-renewal capability),higher differentiation potential,overexpressed stem cell markers,stronger subcutaneous tumorigenicity in NOD/SCID mice than CD90^-cells.Conclusion CD90 may be a potential marker for sorting ovarian cancer stem cells.

关 键 词：卵巢癌 CD90 卵巢癌干细胞 

分 类 号：R737.31[医药卫生—肿瘤]